1. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions.
- Author
-
Saverino D, Fabbi M, Ghiotto F, Merlo A, Bruno S, Zarcone D, Tenca C, Tiso M, Santoro G, Anastasi G, Cosman D, Grossi CE, and Ciccone E
- Subjects
- Antibodies, Monoclonal analysis, Antibodies, Monoclonal metabolism, CD3 Complex physiology, CD4-Positive T-Lymphocytes immunology, Calcium Signaling immunology, Clone Cells immunology, Clone Cells metabolism, Cytoplasm immunology, Cytoplasm metabolism, Cytotoxicity Tests, Immunologic, Cytotoxicity, Immunologic immunology, Epitopes, T-Lymphocyte immunology, Humans, Immunologic Memory immunology, Immunosuppressive Agents immunology, Interphase immunology, Intracellular Fluid immunology, Intracellular Fluid metabolism, Leukocyte Immunoglobulin-like Receptor B1, Lymphocyte Activation immunology, Membrane Glycoproteins immunology, Membrane Glycoproteins metabolism, RNA, Messenger biosynthesis, Receptor-CD3 Complex, Antigen, T-Cell physiology, Receptors, Immunologic genetics, Receptors, Immunologic metabolism, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic metabolism, Antigens, CD, Down-Regulation immunology, Receptors, Immunologic biosynthesis, Receptors, Immunologic immunology, T-Lymphocytes immunology, T-Lymphocytes metabolism
- Abstract
The inhibitory molecule CD85/LIR-1/ILT2 has been detected previously on the surface of a small proportion of T lymphocytes. In this study, evidence is provided that, although only a fraction of CD3+ cells are stained by mAb specific for CD85/LIR-1/ILT2 on their surface, this inhibitory receptor is present in the cytoplasm of all T lymphocytes, and that it is detectable on the surface of all T cell clones by the M402 mAb. Biochemical analyses further demonstrate that CD85/LIR-1/ILT2 is present in all T clones analyzed, and that the protein is tyrosine-phosphorylated. Expression of mRNA coding for CD85/LIR-1/ILT2 has been assessed by RT-PCR. Notably, in the NKL cell line and in one T cell clone, amplification of the messenger required 30 cycles only, whereas, in other T cell clones, an amplification product was detected by increasing the number of cycles. CD85/LIR-1/ILT2 inhibits CD3/TCR-mediated activation in both CD4+ and CD8+ clones, and it down-regulates Ag recognition by CD8+ cells in a clonally distributed fashion. Addition of anti-ILT2 HP-F1 mAb in the cytolytic assay enhances target cell lysis mediated by Ag-specific CTL. This could be due to interference of the mAb with receptor/ligand interactions. In contrast, HP-F1 mAb cross-linking triggers inhibitory signals that reduce cytotoxicity. CD85/LIR-1/ILT2 also controls responses to recall Ags and, in low responders, its engagement sharply increases T cell proliferation. The inhibitory function of the molecule is also confirmed by its ability to reduce CD3/TCR-induced intracellular Ca2+ mobilization.
- Published
- 2000
- Full Text
- View/download PDF